Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis
Comprehensive 22-year singular institutional data affirm CRS and HIPEC yield promising long-term survival for PMP, with 62% 5-year overall survival.
Histopathological grade, completeness of cytoreduction (CC0-1), and tumor markers such as CEA significantly influence prognosis.
Recent studies favor cisplatin plus docetaxel HIPEC regimens, urine-guided intraoperative hydration reduces AKI risk, and perioperative nutritional support enhances recovery.
Nomograms and prognostic classifications (PSOGI) improve individual patient risk stratification and clinical decision-making.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.